Topic: mergers and acquisitions
Analysts are cautiously optimistic Amgen's $13.4 billion purchase of Celgene's psoriasis blockbuster Otezla will pay off.
Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.
W2O Group added its third acquisition in just over a month with Radius Digital Science, following the purchases of ISO.health and Arcus Medica.
With one member of its "big 5" already approved, Celgene has just received a second with the FDA nod for blockbuster hopeful anemia med Reblozyl.
Paul Campanelli was a steady hand after years of turmoil at Endo. Now, with the drugmaker facing rough seas ahead, it will look for a new leader.
Hey, AbbVie: Botox may be a long-term winner, but not every drug in Allergan's stable is shining quite so brightly.
Bristol-Myers' Eliquis is keeping up with its world-beater rep, but analysts worry about I-O med Opdivo—and execs say the med faces a tough 2020.
With Mylan and Pfizer's Upjohn merger up for FTC review, the generics maker's execs are due for big paydays once the deal closes, an SEC filing shows.
What's taking Novartis' Sandoz and Aurobindo so long in their $1 billion U.S. generics oral solids and dermatology deal? FTC happened.
AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.